

**Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: A randomized, placebo-controlled, crossover study (The MOVE Study)**


**Supplementary material**

Henrik Watz,<sup>1</sup> Claudia Mailänder,<sup>2</sup> Monika Baier,<sup>2</sup> Anne Kirsten<sup>1</sup>


<sup>1</sup>Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway Research Center North, Member of the German Center for Lung Research, Woehrendamm 80, D-22927 Grosshansdorf, Germany

<sup>2</sup>Novartis Pharma GmbH, Nuremberg, Germany

Supplementary Figure 1. Raw mean peak inspiratory capacity after 21 days, overall and for each treatment period (full analysis set)



Supplementary Figure 2. Raw mean activity-related energy expenditure, overall and for each treatment period (full analysis set)



Supplementary Figure 3. LS mean change from baseline in activity-related energy expenditure, by median baseline FEV<sub>1</sub> and IC (full analysis set)

